trending Market Intelligence /marketintelligence/en/news-insights/trending/l8ahvx8dWVGmj1MDtjCBog2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

CRISPR, Intellia, Caribou, ERS Genomics sign agreement for gene editing tech IP

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CRISPR, Intellia, Caribou, ERS Genomics sign agreement for gene editing tech IP

CRISPR Therapeutics signed a global cross-consent and invention management agreement with Intellia Therapeutics Inc., Caribou Biosciences and ERS Genomics for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

Under the agreement, the parties will maintain and coordinate the prosecution, defense and enforcement of the shared CRISPR/Cas9 foundational patent portfolio worldwide. Additionally, co-owners of the intellectual property will allow cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.

Other parties to the agreement include intellectual property co-owners Regents of the University of California, Emmanuelle Charpentier and the University of Vienna.